Chapter 4

Pitavastatin and Cancer: Current and Future Prospects

Saeb Aliwaini*

Abstract

Pitavastatin is a synthetic 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor, which was approved for the primary treatment of hypercholesterolemia and combined dyslipidemia since 2009. Today, in vitro and in vivo studies have shown pitavastatin as a potentially effective therapeutic agent for different cancers, including; liver, ovarian, breast, skin, and intestinal cancers. These studies have evaluated pitavastatin both as a single treatment and in combination with other therapeutic options. This chapter focuses on the potential anti-cancer effects of pitavastatin, including its mechanism of action as well as the potential adverse reactions linked to its clinical use.

Total Pages: 132-153 (22)

Purchase Chapter  Book Details